small molecule

LANREOTIDE ACETATE

LANREOTIDE ACETATE

Loss of exclusivityMarch 2027FDA regulatory exclusivity expiry
CompanyAMNEAL EU LTD

Drug detail

Brand nameLANREOTIDE ACETATE
Active ingredientLANREOTIDE ACETATE
StrengthEQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalSeptember 2026
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTMarch 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.